Almonty Industries Shares Jump 8% After Stifel Sets $25 Target 
OpenAI Agents Access U.S. Government Websites During Testing 
EQT Plans €1.7 Billion Sale of Parques Reunidos Stake 
Novo Nordisk Strikes €1.17 Billion Nanexa Drug Delivery Deal 
France Keeps Top Health Alert as Officials Brace for Another Heatwave 
Eli Lilly Eyes AtaiBeckley Acquisition to Expand Psychedelic Mental Health Pipeline 
New Mexico Measles Outbreak Cost Reached $5.4 Million, Study Finds 
Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race 
BlackBerry Shares Rise as Q2 Earnings, Revenue Beat Estimates 
AMD Hits $1 Trillion as BofA Raises Price Target to $720 
FDA Weighs Safety Standards for Psychedelic Therapies 
Venezuela Earthquake Health Risks Rise as Disease Monitoring Intensifies 
Former OpenAI Data Center Chief Chris Malone Joins Nvidia 
BMW 2028 Margin Target Could Fall Below Consensus, UBS Says 
Alcohol is one of the most dangerous drugs, yet its presence is ubiquitous in social settings and celebrations 
SK Biopharmaceuticals Secures Global Rights to Biohaven Epilepsy Drug Opakalim 
TikTok Reaches $100 Million Alabama Settlement Over Child Safety Claims 
Add as a preferred source on Google
AstraZeneca (LON: AZN) reported stronger-than-expected second-quarter earnings on Monday, reaffirming its 2026 guidance as robust demand for its Oncology and Rare Disease portfolio continued to offset the impact of Farxiga's U.S. patent expiry.
The British pharmaceutical company posted core earnings of $2.63 per share for the quarter ended June 30, an 18% increase from a year earlier and above analysts' consensus estimate of $2.48 per share. Revenue rose 5% at constant exchange rates to $15.38 billion, narrowly missing analyst expectations of $15.39 billion.
Investor sentiment remained positive, with AstraZeneca shares rising about 1% in London trading following the results. The company reported operating profit of $3.16 billion, pre-tax profit of $2.8 billion, and a core operating margin of 34%.
AstraZeneca maintained its full-year 2026 outlook, forecasting low double-digit growth in core earnings per shareand mid-to-high single-digit revenue growth. The company also said favorable foreign exchange rates could provide a low single-digit boost to annual revenue if current currency trends continue.
Chief Executive Pascal Soriot acknowledged the disappointing outcome of the CARDIO-TTRansform study but emphasized confidence in the company's long-term growth strategy.
"We remain on track to achieve our ambition of $80 billion in annual revenue by 2030, which factors in both clinical successes and setbacks," Soriot said. He added that AstraZeneca's development pipeline remains strong, with more than 20 major clinical readouts expected over the next 18 months.
Following the earnings release, Bank of America reiterated its Buy rating on AstraZeneca, arguing that upcoming pipeline milestones could support a higher valuation. The brokerage noted the stock trades at roughly 16 times projected 2027 earnings, while its medium-term outlook could justify a valuation closer to 18 times earnings.
The company also provided an update on Ultomiris, reporting that its Phase III trial in adult and adolescent patients with HSCT-TMA did not meet its primary endpoint. However, the pediatric study produced encouraging results, with 87.2% survival at 26 weeks and 73.4% survival at 52 weeks. AstraZeneca said it is moving forward with regulatory submissions for pediatric HSCT-TMA, noting that Ultomiris maintained a safety profile consistent with previous studies and continues to demonstrate a favorable treatment trend in adult and adolescent patients.
